
- Telehealth Visits
- Insurance plan information

Vivek Rudrapatna, MD
Inflammatory Bowel Disease Gastroenterology • Gastroenterology- Telehealth Visits
- Insurance plan information



Vivek Rudrapatna, MD
Inflammatory Bowel Disease Gastroenterology • Gastroenterology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Vivek Rudrapatna is a gastroenterologist who specializes in caring for patients with inflammatory bowel disease (IBD), a condition that has affected his own life. He is also a physician-scientist, a doctor particularly focused on medical research.
Rudrapatna's research applies data mining and artificial intelligence technologies to health care data in order to uncover information that could improve decision making and lead to better outcomes for patients.
Rudrapatna earned his medical degree and a doctorate in cancer genetics at the Icahn School of Medicine at Mount Sinai. He completed a residency in internal medicine at Baylor College of Medicine, followed by a fellowship in gastroenterology at UCSF.
In a ""former life,"" Rudrapatna was a semiprofessional Carnatic (Indian classical) violinist who founded the group Saptaswara, a fusion ensemble blending the sounds of gypsy jazz guitar, bluegrass mandolin, Western violin and north Indian tabla.
Education & training
Board certification
- Gastroenterology, American Board of Internal Med/Gastroenterology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Gastroenterology, UCSF Graduate Medical Education
Residency
- Internal Medicine, Baylor College of Medicine
Internship
- Internal Medicine, Baylor College of Medicine
Degree
- MD, ICAHN School of Medicine at Mount Sinai
My expertise
Locations
My research
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.